Pneumocystis pneumonia
Drug research and approvals for pneumocystis pneumonia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 9 studies of pneumocystis pneumonia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 9
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor ScoreNCT07681583 · Not reported · Azienda Ospedaliero-Universitaria Careggi · starts Nov 13, 2025
- Introduction of Polymerase Chain Reaction (PCR) in Microbiology and ParasitologyNCT07269314 · Not reported · Fondazione IRCCS Policlinico San Matteo di Pavia · starts Sep 1, 2023
- Sulfamethoxazole Prophylaxis Duration After Renal TransplantationNCT07231770 · Not applicable · Anhui Provincial Hospital · starts May 28, 2024
- CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis PneumoniaNCT06892951 · Phase 1 / Phase 2 · University Hospital, Tours · starts Dec 2, 2025
- Optimizing the Diagnosis of Pneumocystis in Immunocompromised PatientsNCT06890078 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Jul 8, 2025
- Caspofungin for Pneumocystis Pneumonia in PLWHIV.NCT06691321 · Not reported · Instituto Nacional de Enfermedades Respiratorias · starts Aug 1, 2023
- Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune…NCT06499233 · Phase 4 · Tongji Hospital · starts Jul 20, 2024
- Rezafungin for Treatment of Pneumocystis Pneumonia in HIV AdultsNCT05835479 · Phase 2 · Mundipharma Research Limited · starts Nov 14, 2023
- Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii PneumoniaNCT04851015 · Phase 3 · Todd C. Lee MD MPH FIDSA · starts Nov 28, 2025
Approved 3
- SulfamethoxazoleBacterial dihydropteroate synthase inhibitor
- TrimethoprimBacterial dihydrofolate reductase inhibitor
- AtovaquoneCytochrome b inhibitor
Phase 3 12
- PentamidineDNA inhibitor
- TrimetrexateDihydrofolate reductase inhibitor
- Leucovorin
- DapsoneDihydropteroate synthase 1 inhibitor
- ZidovudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Primaquine
- PyrimethamineDihydrofolate reductase inhibitor
- SulfadoxineDihydropteroate synthetase inhibitor
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- CobicistatCytochrome P450 3A inhibitor
- DarunavirHuman immunodeficiency virus type 1 protease inhibitor
- PafuramidineKinetoplast DNA inhibitor
Phase 2 2
- Co-trimoxazoleBacterial dihydrofolate reductase inhibitor
- RezafunginCandida inhibitor
How its trials ended
95 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 8 whose ending is known, 25% met their primary endpoint, 0% missed it and 75% stopped early.
- Completed, result not reported6669%
- Status unknown1213%
- Ongoing99%
- Stopped: other or unclear44%
- Met its primary endpoint22%
- Stopped: lack of efficacy11%
- Stopped: enrollment or feasibility11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA